tofacitinib
New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC
The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...
NOVEMBER 26, 2024
Upadacitinib Versus Tofacitinib in UC; Etrasimod for Proctitis
Prospective studies that directly compare the efficacy of two different medications remain rare in our field, ...
NOVEMBER 15, 2024
The ABCs of Optimizing Drug Sequencing for IBD
The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...
OCTOBER 13, 2024
Combination Advanced Therapy in the Treatment of Inflammatory Bowel Disease
The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...
SEPTEMBER 5, 2024
Treating Patients With Inflammatory Bowel Disease and Obesity
An estimated 41% of the US population is obese, including 22% of individuals aged 12 to 19 years, while nearly 1 of ...
MAY 10, 2024
Similar Results With Tofacitinib, Ustekinumab After Biologic Failure in Patients With UC
In biologic-experienced patients with ulcerative colitis, tofacitinib and ustekinumab achieve similar rates of ...
JUNE 26, 2023
DDW 2023: In UC, Tofacitinib and Ustekinumab Perform Similarly After Biologic Failure
In biologic-experienced patients with ulcerative colitis, tofacitinib and ustekinumab achieve about the same rate ...
MAY 7, 2023
Report From CCC 2023: Real-World Data Help Optimize Tofacitinib Maintenance in Ulcerative Colitis
Dose de-escalation of tofacitinib appears to be safe and effective for patients with ulcerative colitis, but ...
JANUARY 23, 2023
High-Dose Tofacitinib Cuts Colectomy Rates For Acute Severe UC
A regimen of three daily doses of tofacitinib (Xeljanz, Pfizer) slashed rates of colectomy by nearly 90% in ...
NOVEMBER 10, 2021
FDA Warns of Serious Risks, Including Death, With JAK Inhibitors
The FDA is requiring the addition of warnings about increased risks for cancer, serious cardiovascular events and ...
SEPTEMBER 2, 2021
Tofacitinib Data Shed Light on DVT/PE Rates, Reescalation Success in UC
In July 2019, the FDA added a boxed warning to the package insert of tofacitinib (Xeljanz, Pfizer), cautioning ...
SEPTEMBER 16, 2020
AGA Issues Treatment Recommendations For Moderate to Severe UC
New guidelines from the American Gastroenterological Association call for the use of biologics or the ...
NOVEMBER 6, 2019
